ArticleHypertension (Dallas, Tex. : 1979)2009

Spironolactone attenuates experimental uremic cardiomyopathy by antagonizing marinobufagenin.

Jiang Tian et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.